Chitosan-Cyclodextrin Hydrogel for Joint Pain Relief and Lubrication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for articular disorders, particularly temporomandibular joint disorders (TMDs), lack a composition that effectively combines pharmacological action with viscosupplementation, leading to issues such as systemic side effects and harmful local consequences.
Innovation Solution
A hydrogel composition based on a polymer network of chitosan and anionic cyclodextrin polymers, optionally incorporating a pharmacological agent, providing both pain relief and lubrication without systemic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pharmacological agents are administered systemically for articular disorders, then pain relief is achieved, but systemic side effects and harmful local consequences occur
Solution Approach 1:
The patent applies local quality by formulating pharmacological agents within a hydrogel composition that is injected directly into the articular joint. This ensures the medication is delivered locally to the affected area rather than being administered systemically, thereby achieving pain relief while avoiding systemic side effects. The hydrogel matrix confines the pharmacological agents to the joint space, releasing them locally over time.
Solution Approach 2:
The hydrogel acts as an intermediary carrier that facilitates controlled local release of pharmacological agents. It serves as a mediator between the pharmacological substance and the articular tissue, allowing gradual release while preventing systemic absorption. The hydrogel matrix controls the diffusion and degradation rates, ensuring safe local delivery.
2Reliability
If hyaluronic acid is used for viscosupplementation, then lubrication is improved, but it does not provide pharmacological action
Solution Approach 1:
The patent merges viscosupplementation and pharmacological action into a single hydrogel composition. It combines hyaluronic acid (or alternative viscosupplementary agents) with pharmacological agents within the same hydrogel matrix, allowing the composition to provide both lubrication and pain relief simultaneously. This integration eliminates the need for separate injections and achieves dual therapeutic effects.
Solution Approach 2:
The hydrogel composition achieves multi-functionality by simultaneously providing viscosupplementation, pharmacological action, and controlled release. The same formulation serves multiple therapeutic purposes: lubricating the joint, delivering pain-relief medication, and potentially promoting tissue repair, making it a universal treatment solution for articular disorders.
3Reliability
If existing treatments are used for articular disorders, then symptom relief is achieved, but cartilage degradation and bone resorption continue
Solution Approach 1:
The hydrogel composition provides continuous useful action through controlled sustained release of pharmacological agents over several weeks. This continuous local delivery maintains therapeutic concentrations at the joint site, providing ongoing pain relief while simultaneously protecting cartilage and bone from degradation, rather than offering only temporary symptom relief.
Solution Approach 2:
The patent utilizes parameter changes in the hydrogel matrix, such as controlling degradation rate, porosity, and pharmacological agent release kinetics, to achieve both symptom relief and tissue protection. By adjusting these parameters, the composition maintains adequate drug levels for pain relief while avoiding excessive doses that could harm cartilage and bone.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hydrogel composition offers prolonged pain relief and lubrication, maintaining viscoelastic properties for two to three weeks, and controlled local release of pharmacological agents, avoiding toxicity and tissue damage.
Implementation Method 1
maintaining viscoelastic properties for two to three weeks
Implementation Method 2
controlled local release of pharmacological agents
Data Source
AI summary
The present disclosure relates to a hydrogel composition based on anionic cyclodextrin polymers and chitosan for use in the treatment of articular disorders. In particular, the hydrogel combines a pharmacological action, in particular an analgesic action, with a visco-supplementation (a lubricating effect).